Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

Q3 2022 EPS Estimates for Pharming Group Cut by Oppenheimer (NASDAQ:PHAR)

Defense World ·  {{timeTz}}

Pharming Group (NASDAQ:PHAR – Get Rating) – Oppenheimer cut their Q3 2022 earnings per share estimates for Pharming Group in a report issued on Friday, August 5th. Oppenheimer analyst H. Singh now anticipates that the company will earn $0.00 per share for the quarter, down from their previous forecast of $0.01. The consensus estimate for Pharming Group's current full-year earnings is $0.02 per share. Oppenheimer also issued estimates for Pharming Group's FY2023 earnings at $0.01 EPS and FY2026 earnings at $0.05 EPS.

Get Pharming Group alerts:

Pharming Group (NASDAQ:PHAR – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported $0.05 EPS for the quarter. The company had revenue of $46.62 million during the quarter, compared to analysts' expectations of $48.00 million.

Pharming Group Stock Up 3.1 %

Shares of PHAR opened at $9.18 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.56 and a quick ratio of 4.90. The business's 50 day moving average price is $7.79 and its 200-day moving average price is $8.34. Pharming Group has a 52 week low of $6.10 and a 52 week high of $11.05.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Cowen Prime Advisors LLC lifted its holdings in Pharming Group (NASDAQ:PHAR – Get Rating) by 134.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,800 shares of the company's stock after acquiring an additional 8,500 shares during the period. Cowen Prime Advisors LLC's holdings in Pharming Group were worth $132,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

(Get Rating)

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.

Featured Articles

  • Get a free copy of the research report on Pharming Group (PHAR)
  • Electric Vehicles Can Drive Alcoa Stock Higher
  • Can Airbnb Still Thrive in a Recession?
  • ConocoPhillips Shares Advance On Strong Q2 Revenue
  • What to Expect from the Markets in a Recession
  • MarketBeat: Week in Review 8/1 – 8/5

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top